UniCycive Therapeutics Inc (UNCY)

[Whalatane]

OT. DRTS ..A co my wife's interested in ( Oncology )
Key Drivers Behind the Surge

Impressive Brain Cancer Data: On May 11, 2026, the company announced initial results from its U.S. REGAIN trial for recurrent glioblastoma. The data revealed a 100% local disease control rate and a 67% complete response rate in the first treated patients, alongside a favorable safety profile.

Wall Street Price Target Hikes:
Following the positive trial data, major financial firms aggressively raised their outlooks. H.C. Wainwright raised its price target to $15.00 from $12.00, while Ladenburg Thalmann also lifted its target to $14.00, both maintaining strong Buy ratings.

Pipeline Momentum:
The brain cancer breakthrough follows a string of recent catalysts, including a reported 100% local disease control rate in pancreatic cancer trials showcased at Digestive Disease Week 2026, and the completion of patient enrollment for its pivotal U.S. skin cancer study.

Upcoming High-Profile Presentations:
Investor enthusiasm continues to build ahead of the 2026 ASCO Annual Meeting (May 29–June 2), where the company is scheduled to present pooled pancreatic cancer data.

Kiwi